{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:39:03Z","timestamp":1793605143139,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Talent Support Plan of Shaanxi Provincial People's Hospital","award":["2021JY-33"],"award-info":[{"award-number":["2021JY-33"]}]},{"name":"Science and Technology Development Incubation Fund of Shaanxi Provincial People's Hospital","award":["2020YXM-13"],"award-info":[{"award-number":["2020YXM-13"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-024-02050-9","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T04:27:49Z","timestamp":1726028869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["TCEB2\/HIF1A signaling axis promotes chemoresistance in ovarian cancer cells by enhancing glycolysis and angiogenesis"],"prefix":"10.1186","volume":"29","author":[{"given":"Zhuo","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"issue":"1","key":"2050_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2020.07.008","volume":"159","author":"L Zheng","year":"2020","unstructured":"Zheng L, et al. Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990\u20132017. Gynecol Oncol. 2020;159(1):239\u201347.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"2050_CR2","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1111\/jog.15019","volume":"47","author":"D Yang","year":"2021","unstructured":"Yang D, et al. Global, regional, and national burden of ovarian cancer and the attributable risk factors in all 194 countries and territories during 2007\u20132017: a systematic analysis of the global burden of disease study 2017. J Obstet Gynaecol Res. 2021;47(12):4389\u2013402.","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"2050_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13148-018-0602-0","volume":"11","author":"S Moufarrij","year":"2019","unstructured":"Moufarrij S, et al. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics. 2019;11(1):7.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"2050_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118878","volume":"1868","author":"L Hao","year":"2021","unstructured":"Hao L, et al. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. Biochim Biophys Acta Mol Cell Res. 2021;1868(1): 118878.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"11","key":"2050_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/s41419-019-2081-4","volume":"10","author":"M Kleih","year":"2019","unstructured":"Kleih M, et al. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 2019;10(11):851.","journal-title":"Cell Death Dis"},{"issue":"16","key":"2050_CR6","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1002\/cam4.2560","volume":"8","author":"A Chandra","year":"2019","unstructured":"Chandra A, et al. Ovarian cancer: current status and strategies for improving therapeutic outcomes. Cancer Med. 2019;8(16):7018\u201331.","journal-title":"Cancer Med"},{"issue":"6","key":"2050_CR7","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3390\/cells9061402","volume":"9","author":"S Mu\u00f1oz-Galv\u00e1n","year":"2020","unstructured":"Mu\u00f1oz-Galv\u00e1n S, Carnero A. Targeting cancer stem cells to overcome therapy resistance in ovarian cancer. Cells. 2020;9(6):1402.","journal-title":"Cells"},{"key":"2050_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577869","volume":"11","author":"C Yang","year":"2020","unstructured":"Yang C, et al. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. Front Immunol. 2020;11: 577869.","journal-title":"Front Immunol"},{"issue":"24","key":"2050_CR9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.21037\/atm-20-4497","volume":"8","author":"JA Perez-Fidalgo","year":"2020","unstructured":"Perez-Fidalgo JA, et al. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med. 2020;8(24):1705.","journal-title":"Ann Transl Med"},{"issue":"26","key":"2050_CR10","doi-asserted-by":"publisher","first-page":"8206","DOI":"10.7150\/thno.37455","volume":"9","author":"L He","year":"2019","unstructured":"He L, et al. Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. Theranostics. 2019;9(26):8206\u201320.","journal-title":"Theranostics"},{"key":"2050_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s11658-017-0058-9","volume":"23","author":"Y Chen","year":"2018","unstructured":"Chen Y, et al. VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer. Cell Mol Biol Lett. 2018;23:2.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"2050_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13073-022-01050-w","volume":"14","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, et al. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response. Genome Med. 2022;14(1):45.","journal-title":"Genome Med"},{"issue":"1","key":"2050_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3892\/or.2015.4388","volume":"35","author":"Z Deng","year":"2016","unstructured":"Deng Z, et al. TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer. Oncol Rep. 2016;35(1):359\u201365.","journal-title":"Oncol Rep"},{"issue":"11","key":"2050_CR14","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1038\/s41418-023-01228-8","volume":"30","author":"M Mu","year":"2023","unstructured":"Mu M, et al. USP51 facilitates colorectal cancer stemness and chemoresistance by forming a positive feed-forward loop with HIF1A. Cell Death Differ. 2023;30(11):2393\u2013407.","journal-title":"Cell Death Differ"},{"issue":"4","key":"2050_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41419-019-1507-3","volume":"10","author":"L Tedesco","year":"2019","unstructured":"Tedesco L, et al. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME. Cell Death Dis. 2019;10(4):266.","journal-title":"Cell Death Dis"},{"issue":"30","key":"2050_CR16","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1038\/s41388-021-01900-8","volume":"40","author":"L Zhao","year":"2021","unstructured":"Zhao L, et al. NF-\u03baB-activated SPRY4-IT1 promotes cancer cell metastasis by downregulating TCEB1 mRNA via Staufen1-mediated mRNA decay. Oncogene. 2021;40(30):4919\u201329.","journal-title":"Oncogene"},{"issue":"2","key":"2050_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.euf.2019.11.013","volume":"7","author":"RG DiNatale","year":"2021","unstructured":"DiNatale RG, et al. Putative drivers of aggressiveness in TCEB1-mutant renal cell carcinoma: an emerging entity with variable clinical course. Eur Urol Focus. 2021;7(2):381\u20139.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"2050_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s12967-021-03057-0","volume":"19","author":"J Bi","year":"2021","unstructured":"Bi J, et al. Establishment of a novel glycolysis-related prognostic gene signature for ovarian cancer and its relationships with immune infiltration of the tumor microenvironment. J Transl Med. 2021;19(1):382.","journal-title":"J Transl Med"},{"issue":"1","key":"2050_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/cancers11010033","volume":"11","author":"Y Ma","year":"2018","unstructured":"Ma Y, et al. Ovarian cancer relies on glucose transporter 1 to fuel glycolysis and growth: anti-tumor activity of BAY-876. Cancers. 2018;11(1):33.","journal-title":"Cancers"},{"key":"2050_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.canlet.2019.10.029","volume":"469","author":"T Gao","year":"2020","unstructured":"Gao T, et al. SIK2 promotes reprogramming of glucose metabolism through PI3K\/AKT\/HIF-1\u03b1 pathway and Drp1-mediated mitochondrial fission in ovarian cancer. Cancer Lett. 2020;469:89\u2013101.","journal-title":"Cancer Lett"},{"issue":"40","key":"2050_CR21","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.1038\/s41388-021-01957-5","volume":"40","author":"H Li","year":"2021","unstructured":"Li H, et al. FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C-MYC\/STAT3 signaling axis in ovarian cancer. Oncogene. 2021;40(40):5938\u201349.","journal-title":"Oncogene"},{"issue":"22","key":"2050_CR22","doi-asserted-by":"publisher","first-page":"8222","DOI":"10.1002\/cam4.4317","volume":"10","author":"D Zhang","year":"2021","unstructured":"Zhang D, et al. Identification of a glycolysis-related gene signature for survival prediction of ovarian cancer patients. Cancer Med. 2021;10(22):8222\u201337.","journal-title":"Cancer Med"},{"issue":"1","key":"2050_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13048-021-00881-2","volume":"14","author":"J Zheng","year":"2021","unstructured":"Zheng J, et al. Comprehensive analyses of glycolysis-related lncRNAs for ovarian cancer patients. J Ovarian Res. 2021;14(1):124.","journal-title":"J Ovarian Res"},{"issue":"9","key":"2050_CR24","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3390\/cells10092371","volume":"10","author":"SH Lee","year":"2021","unstructured":"Lee SH, Golinska M, Griffiths JR. HIF-1-independent mechanisms regulating metabolic adaptation in hypoxic cancer cells. Cells. 2021;10(9):2371.","journal-title":"Cells"},{"issue":"1","key":"2050_CR25","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41467-021-21535-3","volume":"12","author":"F Zheng","year":"2021","unstructured":"Zheng F, et al. The HIF-1\u03b1 antisense long non-coding RNA drives a positive feedback loop of HIF-1\u03b1 mediated transactivation and glycolysis. Nat Commun. 2021;12(1):1341.","journal-title":"Nat Commun"},{"issue":"1","key":"2050_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13046-022-02252-1","volume":"41","author":"Y Chen","year":"2022","unstructured":"Chen Y, et al. TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1\u03b1 degradation. J Exp Clin Cancer Res. 2022;41(1):44.","journal-title":"J Exp Clin Cancer Res"},{"key":"2050_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117846","volume":"255","author":"D Dong","year":"2020","unstructured":"Dong D, et al. Bcl2 inhibitor ABT737 reverses the Warburg effect via the Sirt3-HIF1\u03b1 axis to promote oxidative stress-induced apoptosis in ovarian cancer cells. Life Sci. 2020;255: 117846.","journal-title":"Life Sci"},{"issue":"1","key":"2050_CR28","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s42003-022-03495-6","volume":"5","author":"B Horst","year":"2022","unstructured":"Horst B, et al. Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancers. Commun Biol. 2022;5(1):536.","journal-title":"Commun Biol"},{"issue":"2","key":"2050_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/mc.22506","volume":"56","author":"K Zhang","year":"2017","unstructured":"Zhang K, et al. Cinnamon extract reduces VEGF expression via suppressing HIF-1\u03b1 gene expression and inhibits tumor growth in mice. Mol Carcinog. 2017;56(2):436\u201346.","journal-title":"Mol Carcinog"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-02050-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-024-02050-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-024-02050-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T04:39:18Z","timestamp":1726029558000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-024-02050-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2050"],"URL":"https:\/\/doi.org\/10.1186\/s40001-024-02050-9","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"1 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients gave informed consent and signed an informed consent form. All samples obtained in this study were approved by the ethics committee of the Shaanxi Provincial People\u2019s Hospital and abided by the ethical guidelines of the Declaration of Helsinki. All animal experiments comply with the guidelines for the care and use of laboratory animals established by the National Institutes of Health (Bethesda, Maryland, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"456"}}